Literature DB >> 32168438

Case series: Adolescent victims of the vaping public health crisis with pulmonary complications.

Alexandra P Kass1, Daniel L Overbeek2,3, Laura E Chiel1, Edward W Boyer3, Alicia M H Casey1.   

Abstract

Alongside the epidemic use of electronic cigarettes (e-cigarettes) across the country, evidence of multiple pulmonary complications has emerged, with the most immediately life-threatening being the new clinical condition of e-cigarette/vaping-associated lung injury (EVALI), with investigation actively underway to further define this entity and determine the cause or causes. We present a series of cases of respiratory illnesses associated with e-cigarette use, many of which meet criteria for suspected or confirmed EVALI, managed at a pediatric tertiary care center, demonstrating notable variation in presenting symptoms and severity. Most cases improved with supportive respiratory care and the administration of corticosteroids and antibiotics, although generally no infection was found. The cases also tend to show improvement with discontinuation of the use of e-cigarettes. We discuss challenges in determining the contribution of e-cigarettes to the case pathology and review possible diagnostic and treatment options. In patients suffering from e-cigarette-related respiratory illness including EVALI, the primary treatment goal should be the cessation of e-cigarette use and avoidance of other possible pulmonary toxins, including conventional cigarettes. Prevention of e-cigarette use is critical in the youth population, as these patients are typically nicotine naïve and do not engage in smoking conventional cigarettes before initiation of vaping.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  EVALI; THC; electronic cigarettes; nicotine; vaping-associated lung injury

Year:  2020        PMID: 32168438     DOI: 10.1002/ppul.24729

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  7 in total

Review 1.  Cannabis Vaping Among Youth and Young Adults: a Scoping Review.

Authors:  Melissa B Harrell; Stephanie L Clendennen; Aslesha Sumbe; Kathleen R Case; Dale S Mantey; Sunaina Swan
Journal:  Curr Addict Rep       Date:  2022-05-07

2.  Improvement in Pulmonary Function Following Discontinuation of Vaping or E-Cigarette Use in Adolescents with EVALI.

Authors:  Stanley A Lee; Edouard Sayad; Naga Jaya Smitha Yenduri; Kevin Yuqi Wang; Robert Paul Guillerman; Harold J Farber
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2021-03       Impact factor: 1.349

Review 3.  The chemistry and toxicology of vaping.

Authors:  Emily Bonner; Yvonne Chang; Emerson Christie; Victoria Colvin; Brittany Cunningham; Daniel Elson; Christine Ghetu; Juliana Huizenga; Sara J Hutton; Siva K Kolluri; Stephanie Maggio; Ian Moran; Bethany Parker; Yvonne Rericha; Brianna N Rivera; Samantha Samon; Trever Schwichtenberg; Prarthana Shankar; Michael T Simonich; Lindsay B Wilson; Robyn L Tanguay
Journal:  Pharmacol Ther       Date:  2021-03-19       Impact factor: 13.400

4.  Acute injury or illness related to the inhalation of vaping aerosols among children and adolescents across Canada: A cross-sectional survey of Canadian paediatricians.

Authors:  Sarah Zutrauen; Minh T Do; Lina Ghandour; Charlotte Moore-Hepburn; Suzanne Beno; Sarah A Richmond; Nicholas Chadi
Journal:  Paediatr Child Health       Date:  2021-08-23       Impact factor: 2.600

Review 5.  An update on controversies in e-cigarettes.

Authors:  Jayesh Mahendra Bhatt; Manisha Ramphul; Andrew Bush
Journal:  Paediatr Respir Rev       Date:  2020-09-26       Impact factor: 2.726

Review 6.  Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.

Authors:  Shawn J Rice; Victoria Hyland; Madhusmita Behera; Suresh S Ramalingam; Paul Bunn; Chandra P Belani
Journal:  J Thorac Oncol       Date:  2020-08-29       Impact factor: 15.609

Review 7.  Vaping-Associated Lung Injury: A Review.

Authors:  Marissa O'Callaghan; Niamh Boyle; Aurelie Fabre; Michael P Keane; Cormac McCarthy
Journal:  Medicina (Kaunas)       Date:  2022-03-10       Impact factor: 2.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.